Abstract:The observable mutated isoforms of epidermal growth factor receptor (EGFR) are important considerable therapeutic benchmarks in moderating the non-small cell lung cancer (NSCLC). Recently, quinazoline-based ATP competitive inhibitors have been developed against the EGFR; however, these imply the mutation probabilities, which contribute to the discovery of high probable novel inhibitors for EGFR mutants. Therefore, SAR-based bioactivity analysis, molecular docking and computational toxicogenomics approaches were performed to identify and evaluate new analogs of gefitinib against the ligand-binding domain of the EGFR double-mutated model. From the diverse groups of molecular clustering and molecular screening strategies, top high-binding gefitinib-analogues were identified and studied against EGFR core cavity through three-phase ensemble docking approach. Resulted high possible leads showed good binding orientations than gefitinib (positive control) thus they were subjected to pharmacophore analysis that possesses possible molecular assets to tight binding with EGFR domain. Residues Ser720, Arg841 and Trp880 were observed as novel hot spots and involved in H-bonds, pi-stacking and π-cation interactions that contribute additional electrostatic potency to sustain stability and complexity of protein-ligand complexes, thus they have ability to profoundly adopted by pharmacophoric features. Furthermore, lead molecules have an inhibition percent probability, anticancer potency, toxic impacts, flexible pharmacokinetics, potential gene-chemical interactions towards EGFR were revealed by computational systems biology tools. Our multiple screening strategies confirmed that the druggable sub-pocket was crucial to strong EGFR-ligand binding. The essential pharmacophoric features of ligands provided viewpoints for new inhibitors envisaging, and predicted scaffolds could used as anticancer agents against selected EGFR mutated isoforms.

Single molecule tracking based drug screening

A drug discovery platform to identify compounds that inhibit EGFR triple mutants

A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanisms

A sensitive and microscale method for drug screening combining affinity probes and single molecule fluorescence correlation spectroscopy.

Screening and Identification of Small Molecule Compounds Perturbing Mitosis Using Time-Dependent Cellular Response Profiles.

Image-based phenotypic profiling of a chemogenomic screening library identifies novel druggable targets in the EGFR-pathway

Discovery of VEGF-KDR Binding Inhibitors by Screening Small-Molecule Microarrays with Label-Free Ellipsometric Scanners

Single-molecule Dynamic In-Solution Inhibition Assay: A Method for Full Kinetic Profiling of Drug Candidate Binding to GPCRs in Native Membranes

Using Ligand-Induced Conformational Change to Screen for Compounds Targeting G-Protein-Coupled Receptors

High-Throughput Screening Based on Label-Free Detection of Smallmolecule Microarrays

Simultaneous detection of intracellular target and off-target binding of small molecule cancer drugs at nanomolar concentrations

Fragment-based screening of enzyme drug targets : Microfluidic mobility shift assay improves confidence in candidate selection

In Situ Study of the Drug-target Protein Interaction in Single Living Cells by Combining Fluorescence Correlation Spectroscopy with Affinity Probes.

Long-term single-molecule tracking in living cells using weak-affinity protein labeling

Rapid Screening of Multi-Target Antitumor Drugs by Nonimmobilized Tumor Cells/tissues Capillary Electrophoresis

High-Throughput Screening of Kinase Inhibitors by Multiplex Capillary Electrophoresis with Uv Absorption Detection

Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor

Real-time detection of protein trafficking with high-throughput flow cytometry (HTFC) and fluorogen-activating protein (FAP) base biosensor

Discovery of regulators of receptor internalization with high-throughput flow cytometry

Sensitive Measurement of Drug-Target Engagement by a Cellular Thermal Shift Assay with Multiplex Proximity Extension Readout

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Enabled Drug Discovery Platform